Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Menin-inhibition boosts CAR-T cell therapy against NPM1 mutated and KMT2A-rearranged acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJan HabermannCLCatharina LahrmannMDMichael Delacher

Discussion

Loading...

Member takes

Overview

Observational analysis reveals menin inhibitors boost anti-leukemic activity in NPM1 mutated AML, indicating promise for CAR-T therapy.

Key Points

  • Combined menin inhibition and CLEC12A-targeted CAR-T cells showed notable anti-leukemic effects in vitro and in vivo.
  • Significant enhancement of killing activity was observed in leukemic cells following use of menin inhibitors with CAR-T treatment.
  • Xenograft models confirmed that menin inhibitors induce surface expression of CLEC12A, a crucial target for CAR therapies.
  • Findings support a novel approach in treating acute myeloid leukemia with menin inhibitors enhancing CAR-T cell therapy.

Cite This Study

Habermann et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d75fhttps://doi.org/10.1182/blood-2025-866
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post allo-HCT menin-inhibition enhances graft-versus-leukemia effects by endogenous retrovirus induction in AML and T-cell activation2025
  2. 2Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review2025 · 7 citations
  3. 3The role of menin inhibitors in acute myeloid leukemia2025 · 2 citations
  4. 4Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors2025
  5. 5Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia2025 · 1 citations